Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection
Antibodies can provide antiviral protection through neutralization and recruitment of innate effector functions through the Fc domain. While neutralization has long been appreciated for its role in antibody-mediated protection, a growing body of work indicates that the antibody Fc domain also signif...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1976580 |
| _version_ | 1797673318794395648 |
|---|---|
| author | Bronwyn M. Gunn Shuangyi Bai |
| author_facet | Bronwyn M. Gunn Shuangyi Bai |
| author_sort | Bronwyn M. Gunn |
| collection | DOAJ |
| description | Antibodies can provide antiviral protection through neutralization and recruitment of innate effector functions through the Fc domain. While neutralization has long been appreciated for its role in antibody-mediated protection, a growing body of work indicates that the antibody Fc domain also significantly contributes to antiviral protection. Recruitment of innate immune cells such as natural killer cells, neutrophils, monocytes, macrophages, dendritic cells and the complement system by antibodies can lead to direct restriction of viral infection as well as promoting long-term antiviral immunity. Monoclonal antibody therapeutics against viruses are increasingly incorporating Fc-enhancing features to take advantage of the Fc domain, uncovering a surprising breadth of mechanisms through which antibodies can control viral infection. Here, we review the recent advances in our understanding of antibody-mediated innate immune effector functions in protection from viral infection and review the current approaches and challenges to effectively leverage innate immune cells via antibodies. |
| first_indexed | 2024-03-11T21:42:53Z |
| format | Article |
| id | doaj.art-90e566fa059c4ab4b6f5c019779c60cc |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:42:53Z |
| publishDate | 2021-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-90e566fa059c4ab4b6f5c019779c60cc2023-09-26T12:43:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-11-0117114328434410.1080/21645515.2021.19765801976580Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protectionBronwyn M. Gunn0Shuangyi Bai1Washington State UniversityWashington State UniversityAntibodies can provide antiviral protection through neutralization and recruitment of innate effector functions through the Fc domain. While neutralization has long been appreciated for its role in antibody-mediated protection, a growing body of work indicates that the antibody Fc domain also significantly contributes to antiviral protection. Recruitment of innate immune cells such as natural killer cells, neutrophils, monocytes, macrophages, dendritic cells and the complement system by antibodies can lead to direct restriction of viral infection as well as promoting long-term antiviral immunity. Monoclonal antibody therapeutics against viruses are increasingly incorporating Fc-enhancing features to take advantage of the Fc domain, uncovering a surprising breadth of mechanisms through which antibodies can control viral infection. Here, we review the recent advances in our understanding of antibody-mediated innate immune effector functions in protection from viral infection and review the current approaches and challenges to effectively leverage innate immune cells via antibodies.http://dx.doi.org/10.1080/21645515.2021.1976580antibodieseffector functionsinnate immunityantibody engineeringantibody fc domainvirusantiviralimmuno-therapeuticsebola virussars-cov-2influenza |
| spellingShingle | Bronwyn M. Gunn Shuangyi Bai Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection Human Vaccines & Immunotherapeutics antibodies effector functions innate immunity antibody engineering antibody fc domain virus antiviral immuno-therapeutics ebola virus sars-cov-2 influenza |
| title | Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection |
| title_full | Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection |
| title_fullStr | Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection |
| title_full_unstemmed | Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection |
| title_short | Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection |
| title_sort | building a better antibody through the fc advances and challenges in harnessing antibody fc effector functions for antiviral protection |
| topic | antibodies effector functions innate immunity antibody engineering antibody fc domain virus antiviral immuno-therapeutics ebola virus sars-cov-2 influenza |
| url | http://dx.doi.org/10.1080/21645515.2021.1976580 |
| work_keys_str_mv | AT bronwynmgunn buildingabetterantibodythroughthefcadvancesandchallengesinharnessingantibodyfceffectorfunctionsforantiviralprotection AT shuangyibai buildingabetterantibodythroughthefcadvancesandchallengesinharnessingantibodyfceffectorfunctionsforantiviralprotection |